Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journ
Go back to Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journ| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 15.30 +0.45 (3.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.85 | 52 Week High | $117.12 | |||
| Open | $15.48 | 52 Week Low | $46.52 | |||
| Day High | $16.08 | P/E | N/A | |||
| Day Low | $15.23 | EPS | $-1.97 | |||
| Volume | 11,494,477 | |||||
